Systemic type epstein-barr virus-related lymphoproliferative diseases in children and young adults: Challenges for pediatric hemato-oncologists and infectious disease specialists

Pediatric Hematology and Oncology

Volumn 24, Issue 8, 2007, Pages 563-568

  Imashuku, Shinsaku ^a  

^a Takasago seibu Hospital   (Japan)

Author keywords

Chronic active Epstein Barr virus infection; Epstein Barr virus; Hemophagocytic lymphohistiocytosis; Infectious mononucleosis

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; RITUXIMAB;

CLINICAL FEATURE; DISEASE COURSE; EPSTEIN BARR VIRUS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SPECIALIST; NASOPHARYNX CARCINOMA; NOTE; PLASMAPHERESIS; VIRUS INFECTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; INFECTIOUS MONONUCLEOSIS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; NASOPHARYNGEAL NEOPLASMS;

EID: 37349104881     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701640499     Document Type: Note

References (26)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492.
2. Rickenson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott, Williams & Wilkins; 2001:2575-2627.
3. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44:259-272.
4. Kawa K. Diagnosis and treatment of Epstein-Barr virus-associated natural killer lymphoproliferative disease. Int J Hematol. 2003;78:24-31.
5. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132-136.
6. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood. 2001;98:1882-1888.
7. Imashuku S, Hibi S, Tabata Y, et al. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma. 2000;37:577-584.
8. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118-3125.
9. Mroczek EC, Weisenburger DD, Grierson HL, et al. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med. 1987;111:530-535.
10. Janka G, Henter J-I, Imashuku S. Clinical aspects and therapy of hemophagocytic lymphohistiocytosis. In: Weitzman S, Egeler RM, eds. Histiocytic Disorders of Children and Adults: Basic Science, Clinical Features and Therapy. Cambridge, UK: Cambridge University Press; 2005:353-379.
11. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-131.
12. Ishihara S, Okada S, Wakiguchi H, et al. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr. 1995;84:1271-1275.
13. Murakami K, Ohsawa M, Hu SX, et al. Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. Arthritis Rheum. 1998;41:369-373.
14. Kimura H Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16:251-261.
15. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005;80:64-69.
16. Wada T, Kurokawa T, Toma T, et al. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur J Haematol. 2007;79:72-75.
17. Lin MT, Chang HM, Huang CJ, et al. Massive expansion of EBV+monoclonal T cells with CD5 down regulation in EBV-associated haemophagocytic lymphohistiocytosis. J Clin Pathol. 2007;60:101-103.
18. Takahashi N, Chubachi A, Miura I, et al. Lymphoma-associated hemophagocytic syndrome in Japan. Jpn J Clin Hematol. 1999;40:542-549.
19. Yao M, Cheng A-L, Su I-J, et al. Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus associated T cell lymphoma. Br J Haematol. 1994;87:535-543.
20. Zareifer S, Geramizadeh B, Sharifian M. Simultaneous manifestation of fulminant infectious mononucleosis with B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2007;25:2051-2052.
21. Matsumoto Y, Naniwa D, Banno S, et al. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher. 1998;2:300-304.
22. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994-996.
23. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood. 1999;93:1869-1874.
24. Minegishi M, Ohashi Y, Kumaki S, et al. Successful umbilical cord blood transplantation from an unrelated donor for a patient with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2001;27:883-886.
25. Ishimura M, Ohga S, Nomura A, et al. Successful umbilical cord blood transplantation for severe chronic active Epstein-Barr virus infection after the double failure of hematopoietic stem cell transplantation. Am J Hematol. 2005;80:207-212.
26. Uehara T, Nakaseko C,Hara S, et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. Am J Hematol. 2004;76:368-372.